Cell Therapy News Volume 25.26 | Aug 19 2024

    0
    88








    2024-08-19 | CTN 25.26


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.26 – 19 August, 2024
    TOP STORY

    Removal of TREX1 Activity Enhances CRISPR–Cas9-Mediated Homologous Recombination

    The authors used genome-wide screening in Fanconi anemia patient lymphoblastic cell lines to uncover suppressors of CRISPR–Cas9-mediated homology-directed repair.
    [Nature Biotechnology]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    G-Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy

    In CT26 tumor-bearing mouse model, FMRP degradation within tumors substantially promoted the infiltration of lymphocytes and CD8 T cells and reduced the proportion of Treg cells, reshaping the proinflammatory tumor microenvironment and accordingly transforming cold tumor into hot tumor.
    [Angewandte Chemie-International Edition]

    Abstract

    T Cell Specific In Vivo Gene Delivery with DART-AAVs Targeted to CD8

    Scientists presented DARPin-targeted AAVs (DART-AAVs) displaying DARPins specific for human and murine CD8. Insertion of DARPins into the GH2/GH3 loop of the capsid protein 1 of AAV2 and AAV6 resulted in high selectivity for CD8-positive T cells with unimpaired gene delivery activity.
    [Molecular Therapy]

    AbstractFull ArticleGraphical Abstract

    Gene Panel Predicts Neoadjuvant Chemoimmunotherapy Response and Benefit from Immunotherapy in HER2-Negative Breast Cancer

    Two I-SPY2 cohorts and one West China Hospital cohort of patients treated with neoadjuvant chemoimmunotherapy were included. Machine learning algorithms were used to identify key genes. Principal component analysis was used to calculate the ImPredict score.
    [Journal For Immunotherapy of Cancer]

    Full Article

    Remodeling the Hepatic Immune Microenvironment and Demolishing T Cell Traps to Enhance Immunotherapy Efficacy in Liver Metastasis

    Researchers reported a novel nanomedicine that converts the hepatic immune microenvironment to a “hot” phenotype by targeting hepatic macrophage-centric T cell elimination.
    [Journal of Controlled Release]

    AbstractGraphical Abstract

    First-in-Class Transactivator-Free, Doxycycline-Inducible IL-18-Engineered CAR-T Cells for Relapsed/Refractory B-Cell Lymphomas

    Scientists present the first transactivator-free anti-CD19 CAR-T cells able to control IL-18 expression under ultra-low doses of doxycycline and without altering cellular fitness.
    [Molecular Therapy – Nucleic Acids]

    AbstractGraphical Abstract

    Lentiviral Vector Packaging and Producer Cell Lines Yield Titres Equivalent to the Industry-Standard Four-Plasmid Process Stable Cells for Lentiviral Vector Manufacturing

    Investigators developed lentiviral vector (LVV) packaging and producer cell lines, which reduced or eliminated the need for plasmid transfection during LVV manufacture. To develop a packaging cell line, lentiviral packaging genes were stably integrated by random integration of linearised plasmid DNA.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractFull ArticleGraphical Abstract

    Establishment of a Stem Cell Administration Imaging Method in Bleomycin-Induced Pulmonary Fibrosis Mouse Models

    Researchers administered mouse adipose tissue-derived mesenchymal stem cells (mASCs) labeled with quantum dots to a mouse model of bleomycin-induced pulmonary fibrosis in an effort to clarify the relationship between in vivo dynamics and therapeutic efficacy.
    [Scientific Reports]

    Full Article

    Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity

    Investigators generated a series of adeno-associated viruses (AAV) libraries containing variations at three residues (Y446, N470, and W503) of the galactose-binding pocket of the AAV9 VP1 protein.
    [Human Gene Therapy]

    Abstract
    Tools to isolate, culture, and assay cells. Click to explore.
    REVIEWS

    Regenerative Cell Therapy with 3D Bioprinting

    To fully unleash the potential of cell therapy in regenerative medicine, it is beneficial to adopt, adapt, or develop better tools to produce high-quality cell-based products through various biofabrication techniques.
    [Science]

    Abstract

    Frontiers in CAR-T Cell Therapy for Autoimmune Diseases

    The authors discuss the mechanisms by which CAR-T cells target autoimmune conditions, summarize current preclinical models, and highlight ongoing clinical trials, including CAR-T therapy design, clinical outcomes, and challenges.
    [Trends In Pharmacological Sciences]

    Abstract

    Advancements and Challenges in Stem Cell Transplantation for Regenerative Medicine

    Scientists comprehensively examine recent developments and challenges in stem cell transplantation, exploring the identification and isolation of various stem cell types, including embryonic, induced pluripotent, and adult stem cells derived from multiple sources.
    [Heliyon]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

    Bristol Myers Squibb announced that the European Medicines Agency has validated its Type II variation application to expand the indication for Breyanzi, a CD19-directed CAR T cell therapy, to include the treatment of adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.
    [Bristol Myers Squibb]

    Press Release

    Turnstone Narrows Cell Therapy Focus to ‘High Unmet Need’ Tumor Indications

    Turnstone Biologics is narrowing the focus of Phase I trials of its lead tumor-infiltrating lymphocyte therapy, with cutaneous melanoma and breast cancer no longer in the mix.
    [Fierce Biotech]

    Press Release
    FEATURED EVENT

    22nd Meeting of the EA4HP

    September 21 – 26, 2024
    Dubrovnik, Croatia

    > See All Events

    JOB OPPORTUNITIES

    Scientist – T Cell Stemness

    Lyell – Seattle, Washington, United States

    Research Positions – Senescence in Tissue Regeneration

    Ludwig Boltzmann Institute for Traumatology – Vienna, Austria

    Study Physician – Immunology Cell Therapy

    AstraZeneca – Boston, Massachusetts, United States

    Senior Director – Cell Therapy Portfolio Lead

    Takeda – Boston, Massachusetts, United States

    Postdoctoral Research Associate – Stem Cell Biology and Wound Healing

    The University of Edinburgh – Edinburgh, Scotland, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2